 |
Journal articles
Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice
Abstract : In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and neurodegenerative disorders. Numerous studies suggest that targeting BDNF and its TrkB receptor could be a promising therapeutic strategy for the treatment of brain disorders. However, the development of potent small ligands for the TrkB receptor has proven to be difficult. By using a peptidomimetic approach, we developed a highly potent and selective TrkB inhibitor, cyclotraxin-B, capable of altering TrkB-dependent molecular and physiological processes such as synaptic plasticity, neuronal differentiation and BDNF-induced neurotoxicity. Cyclotraxin-B allosterically alters the conformation of TrkB, which leads to the inhibition of both BDNF-dependent and-independent (basal) activities. Finally, systemic administration of cyclotraxin-B to mice results in TrkB inhibition in the brain with specific anxiolytic-like behavioral effects and no antidepressant-like activity. This study demonstrates that cyclotraxin-B might not only be a powerful tool to investigate the role of BDNF and TrkB in physiology and pathology, but also represents a lead compound for the development of new therapeutic strategies to treat brain disorders.
Cited literature [60 references]
https://www.hal.inserm.fr/inserm-02472181
Contributor : Maxim Cazorla <>
Submitted on : Monday, February 10, 2020 - 9:40:25 AM
Last modification on : Thursday, April 9, 2020 - 11:49:33 AM
Document(s) archivé(s) le : Monday, May 11, 2020 - 1:35:36 PM
Contributor : Maxim Cazorla <>
Submitted on : Monday, February 10, 2020 - 9:40:25 AM
Last modification on : Thursday, April 9, 2020 - 11:49:33 AM
Document(s) archivé(s) le : Monday, May 11, 2020 - 1:35:36 PM
File
Cazorla 2010 PLoS One.pdf
Publication funded by an institution
